skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study

Review

(6621) Views  (1626) Full article downloads

Authors: Prasad Bichu, Ravi Nistala, Asma Khan, James R Sowers, Adam Whaley-Connell

Published Date December 2008 Volume 2009:5 Pages 129 - 140
DOI: http://dx.doi.org/10.2147/VHRM.S3121

Prasad Bichu1, Ravi Nistala1, Asma Khan2, James R Sowers2, Adam Whaley-Connell1

1Divisions of Nephrology and Endocrinology; 2Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia Missouri, USA

Abstract: Diabetic kidney disease is characterized by persistent albuminuria (>300 mg/dl or >200 μg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive decline in the glomerular filtration rate (GFR), elevated arterial blood pressure, and an increased risk for cardiovascular morbidity and mortality. Diabetic kidney disease is the leading cause of end stage renal disease (ESRD) prompting investigators to evaluate mechanisms by which to slow disease progression. One such mechanism is to block the activity of angiotensin II at the receptor site and agents that follow this mechanism are referred to as angiotensin receptor blockers (ARB). There is sufficient clinical evidence to support that ARB have protective effects on kidney function in patients with diabetes and hypertension. However, in the past decade there have been few investigations comparing individual ARBs on renal outcomes. Telmisartan, a lipophilic ARB with a long half-life, has been hypothesized to have a greater anti-proteinuric effect when compared to the shorter acting losartan. Therefore, the A comparison of telMisartan versus losArtan in hypertensive type 2 DiabEtic patients with Overt nephropathy (AMADEO) trial sought to investigate renal and cardiovascular endpoints. In this review, we discuss the pathophysiology of diabetic kidney disease and implications of the AMADEO trial in the context of current understanding from recent outcome trials.

Keywords: diabetic kidney disease, hypertension, telmisartan, AMADEO








Readers of this article also read:

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers
Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidney
Cardioprotective and β-adrenoceptor antagonistic activity of a newly synthesized aryloxypropanolamine derivative PP-36
Effect of amlodipine, a calcium channel antagonist, on gonadal steroid of male wistar albino rats
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Nephroprotection of lacidipine against gentamycin-induced nephrotoxicity in albino rats
Update on the diagnosis and management of acute kidney injury
Angiotensin (1-7)/Mas receptor axis activation ameliorates the changes in fatty acid composition in diabetic rats with nephropathy
Role of aliskiren in blood pressure control and renoprotection
Emerging drug combinations to optimize renovascular protection and blood pressure goals
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University